SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 18, 2003
Introgen Therapeutics, Inc.
| Delaware | 0-21291 | 74-2704230 | ||
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| 301 Congress Avenue, Suite 1850, Austin, Texas | 78701 | |||
| (Address of principal executive offices) | (Zip Code) | |||
| Registrant’s telephone number, including area code: | (512) 708-9310 | |
(Former name or former address, if changed since last report) |
| Item 5. Other Events. | ||||||||
| SIGNATURES | ||||||||
| INDEX TO EXHIBITS | ||||||||
| EX-99.1 Press Release | ||||||||
Item 5. Other Events.
(c) Exhibits.
99.1 Press Release dated June 18, 2003.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: June 18, 2003 | INTROGEN THERAPEUTICS, INC. /s/ G. Thomas Finnegan G. Thomas Finnegan Vice President |
-2-
INDEX TO EXHIBITS
| Exhibit | ||||||||
| Number | Description of Document | |||||||
| 99.1 | Press Release dated June 18, 2003. | |||||||
